Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - sunitinib - capsules - sunitinib 37.5 mg - sunitinib - sunitinib s.k. is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib s.k. is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - sunitinib - capsules - sunitinib 50 mg - sunitinib - sunitinib s.k. is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib s.k. is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - ezetimibe; rosuvastatin as calcium - film coated tablets - ezetimibe 10 mg; rosuvastatin as calcium 10 mg - rosuvastatin and ezetimibe - primary hypercholesterolaemia/homozygous familial hypercholesterolaemia (hofh):rosetemib s.k is indicated for substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products, as adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - ezetimibe; rosuvastatin as calcium - film coated tablets - ezetimibe 10 mg; rosuvastatin as calcium 20 mg - rosuvastatin and ezetimibe - primary hypercholesterolaemia/homozygous familial hypercholesterolaemia (hofh):rosetemib s.k is indicated for substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products, as adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - ezetimibe; rosuvastatin as calcium - film coated tablets - ezetimibe 10 mg; rosuvastatin as calcium 40 mg - rosuvastatin and ezetimibe - primary hypercholesterolaemia/homozygous familial hypercholesterolaemia (hofh):rosetemib s.k is indicated for substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products, as adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - ezetimibe; rosuvastatin as calcium - film coated tablets - ezetimibe 10 mg; rosuvastatin as calcium 5 mg - rosuvastatin and ezetimibe - primary hypercholesterolaemia/homozygous familial hypercholesterolaemia (hofh):rosetemib s.k is indicated for substitution therapy in adult patients who are adequately controlled with rosuvastatin and ezetimibe given concurrently at the same dose level as in the fixed combination, but as separate products, as adjunct to diet for treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or homozygous familial hypercholesterolaemia.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - clofarabine - concentrate for solution for infusion - clofarabine 1 mg / 1 ml - clofarabine - treatment of acute lymphoblastic leukaemia (all) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and who are about to undergo transplantation. safety and efficacy have been assessed in studies of patients < or = 21 years old at initial diagnosis.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - abiraterone acetate - tablets - abiraterone acetate 250 mg - abiraterone - • abiraterone s.k. is cyp 17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. • abiraterone s.k. is indicated for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt).

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg/ml - enoxaparin - enoxaparin inhixa is indicated in adults for:• prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - enoxaparin sodium - solution for injection - enoxaparin sodium 150 mg/ml - enoxaparin - enoxaparin inhixa forte is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).